Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise
Ascendis Pharma (ASND) reported its fourth-quarter 2024 earnings, highlighting a significant revenue increase and a positive market reaction. The company posted total revenue of €173.9 million for the ...
Le Lézard1 小时
U.S. FDA Approves Expanded Label for Astellas' IZERVAYtm (avacincaptad pegol intravitreal ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...